Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial - Archive ouverte HAL Access content directly
Journal Articles Clinical Cancer Research Year : 2020

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial

Thomas Graillon
Marc Sanson
Chantal Campello
  • Function : Author
Ahmed Idbaih
Matthieu Peyre
  • Function : Author
Hadrien Peyrière
  • Function : Author
Noémie Basset
  • Function : Author
Didier Autran
  • Function : Author
Michel Kalamarides
Pierre-Hugues Roche
  • Function : Author
Stéphane Fuentes
  • Function : Author
Emeline Tabouret
Maryline Barrie
  • Function : Author
Anita Cohen
  • Function : Author
Stéphane Honoré
Mohamed Boucekine
  • Function : Author
Karine Baumstarck
  • Function : Author
Anne A. Barlier
Henry Dufour
  • Function : Author

Abstract

Aggressive meningiomas that progress after surgery/radiotherapy represent an unmet medical need. Strong and constant expression of SSTR2A receptors and activation of the Pi3K/Akt/mTOR pathway have been demonstrated in meningiomas. The combination of everolimus, an mTOR inhibitor, and octreotide, a somatostatin agonist, has shown additive antitumor effect in vitro. The phase II CEVOREM trial investigated the efficacy of this combination on recurrent meningiomas.

Dates and versions

hal-03009918 , version 1 (17-11-2020)

Identifiers

Cite

Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, et al.. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial. Clinical Cancer Research, 2020, 26 (3), pp.552-557. ⟨10.1158/1078-0432.CCR-19-2109⟩. ⟨hal-03009918⟩
47 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More